References
- Kung HF. The β-amyloid hypothesis in Alzheimer's disease: seeing is believing. ACS Med Chem Lett 2012;3:265–7
- Dahlgren KK, Manelli AM, Stine WB Jr, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046–53
- Huber PC, Reis GP, Amstalden MC, Lancellotti M. Synthesis, spectroscopic characterizations and antimicrobial activity of copper and zinc complexes of levofloxacin, ciprofloxacin and 3-carboethoxy-quinolone. Polyhedron 2013;57:14–19
- Huber PC, Benevento CE, Castilho RF, Almeida WP. Effect of levofloxacin and 3-carboethoxy-4-quinolone on the β-amyloid fibrils formation. J Chem Pharm Res 2015;7:993–1000
- Pudlo M, Luzet V, Ismaïli L, et al. Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidante hybrids for Alzheimer disease. Biooorg Med Chem 2014;22:2496–507
- Le Goff G, Ouazzani J. Natural hydrazine-containing compounds: biosynthesis, isolation, biological activities and synthesis. Bioorg Med Chem 2014;22:6529–44
- Maia RD, Tesch R, Fraga CAM. Acylhydrazone derivatives: a patent review. Expert Opin Ther Pat 2014;24:1161–70
- Mohareb RM, Fleita DH, Sakka OK. Novel synthesis of hydrazine-hydrazone derivatives and their utilization in the synthesis of coumarin, pyridine, thizole and thiophene derivatives with antitumor activity. Molecules 2011;16:16–27
- Ellis S, Kalinowski DS, Leotta L, et al. Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide. Mol Pharmacol 2014;85:269–78
- Navidpour L, Shafaroodi H, Saeedi-Motahar G, Shafiee A. Synthesis, anti-inflammatory and analgesic activities of arylidene-2-(3-chloroanilino)nicotinic acid hydrazyde. Med Chem Res 2014;23:2793–802
- Massoulié J, Bon S. The C-terminal T peptide of cholinesterases: structure, interactions, and influence on protein folding and secretion. J Mol Neurosci 2006;30:233–6
- Amarante GW, Benassi M, Pascoal RN, et al. Mechanism and synthesis of pharmacologically active quinolones from Morita–Baylis–Hillman adducts. Tetrahedron 2010;66:4370–6
- Srivatava N, Kumar A. Synthesis of substituted-4-oxo-1, 4-dihydro-3-[1-oxo-2-hydrazino-3-{p-toluenesulfon}] quinoline derivatives and their biological activity against bacterial infections. Orient J Chem 2013;29:507–11
- Moerdyk JO, Speelman AL, Kuper III KE, et al. Synthesis and photochemistry of two quinolines analogs of the perimidinespirohexadienone family of photochromes. J Photochem Photobiol A 2009;205:84–92
- Lopez AB, Miguez E, Kummerle AE, et al. Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives. Molecules 2013;18:11683–704
- Blake MG, Krawczyk MC, Baratti CM, Boccia MM. Neuropharmacology of memory consolidation and reconsolidation: Insights on central cholinergic mechanisms. J Physiol Paris 2014;108:286–91
- Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2014;96:255–62
- Johnson G, Moore SW. The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. Curr Pharm Des 2006;12:217–25
- Dikersont TJ, Beuscher IV AE, Rogers CJ, et al. Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library. Biochemistry 2005;44:14845–3
- Inestros NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 2008;275:625–32
- Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999;7:297–307
- Prakash A, Kalra J, Mani V, et al. Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets. Expert Rev Neurother 2015;15:53–71
- Singh M, Kaur M, Kukreja H, et al. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 2013;70:165–88
- Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–7
- GraphPad Prism version 6.04 for Windows, GraphPad Software. La Jolla, CA. Available from: www.graphpad.com
- Multhaup G, Huber O, Buee L, Galas MC. Amyloid precursor protein (APP), metabolites APP, intracellular fragment (AICD), a beta 42 and Tau in nuclear roles. J Biol Chem 2015;39:23515–22
- Puzzo D, Gulisano W, Arancio O, Palmeri A. The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience 2015;307:26–36
- Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698–712
- Mohamed T, Rao PPN. Alzheimer's disease: emerging trends in small molecule therapies. Curr Med Chem 2011;18:4299–320
- Trippier PC, Labby KJ, Hawker DD, Mataka JJ. Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem 2013;56:3121–47
- Krebs MRH, Bromley EHC, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol 2005;149:30–7